{"id":30939,"date":"2023-10-17T18:52:48","date_gmt":"2023-10-17T18:52:48","guid":{"rendered":"https:\/\/prosfunds.com\/investing\/johnson-johnson-beats-earnings-estimates-and-downplays-obesity-drugs-impact-on-its-med-tech-business\/"},"modified":"2023-10-17T18:52:50","modified_gmt":"2023-10-17T18:52:50","slug":"johnson-johnson-beats-earnings-estimates-and-downplays-obesity-drugs-impact-on-its-med-tech-business","status":"publish","type":"post","link":"https:\/\/prosfunds.com\/?p=30939","title":{"rendered":"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business"},"content":{"rendered":"
\n

Johnson & Johnson on Tuesday posted better-than-expected third-quarter earnings and raised its profit guidance while downplaying concerns about how popular obesity drugs could affect its med-tech business.<\/p>\n

The New Brunswick, N.J.-based company posted net income of $4.309 billion, or $1.69 a share, for the quarter, after earnings of $4.31 billion, or $1.62 a share, in the year-earlier period. Adjusted per-share earnings came to $2.66, ahead of the $2.52 FactSet consensus. <\/p>\n

\n

Sales rose 6.8% to $21.351 billion from $19.996 billion a year ago, also ahead of the $21.036 billion FactSet consensus. <\/p>\n

The quarterly results are the company\u2019s first since spinning off its consumer-health business earlier this year into a separate company called Kenvue
\n KVUE,
\n +1.31%<\/bg-quote>.<\/span>
\n Kenvue includes a host of household brands, including Tylenol, Listerine, Band-Aid, Neutrogena and Nicorette.<\/p>\n

Johnson & Johnson reported that its innovative-medicine segment\u2019s sales rose 5.1% from the year-earlier period, to $13.893 billion. The growth was driven in part by cancer drugs Darzalex and Carvykti as well as psoriasis treatment Stelara, which was one of the 10 drugs selected in late August for the first round of Medicare drug-price negotiations under the Inflation Reduction Act. <\/p>\n

In the coming days, Johnson & Johnson is set to release some pipeline news that could be a key catalyst for the stock, analysts say. It will present data on its cancer treatment Rybrevant in combination with its investigational drug lazertinib in non-small-cell lung cancer at the European Society for Medical Oncology conference this weekend. <\/p>\n

Johnson & Johnson reported third-quarter med-tech sales of $7.458 billion, up 10% from the year-earlier period. Procedure volumes in 2024 are expected to be on par with elevated 2023 levels, Chief Financial Officer Joseph Wolk said on the call Tuesday. <\/p>\n

Executives on the call sought to tamp down concerns that popular GLP-1 drugs such as Wegovy and Ozempic could weigh on the growth of the business, which makes devices for bariatric surgery and other procedures that could be affected by use of the drugs. \u201cWe\u2019re seeing some impact in our bariatric business\u201d from the drugs, CEO Joaquin Duato said on the call. \u201cSome patients are reconsidering surgery, expecting to get treatment.\u201d But overall, he said, surgeons believe the popularity of the drugs and increased awareness of obesity could become a tailwind for bariatric surgery. And about 30% of patients won\u2019t be able to tolerate the drugs, he said, \u201cso they would be another funnel for our bariatric business.\u201d <\/p>\n

J&J raised the midpoint of its full-year sales guidance and now expects sales to range from $83.6 billion to $84 billion, up from August guidance of $82.3 billion to $84 billion. <\/p>\n

It expects full-year EPS to range from $10.02 to $10.08, compared with prior guidance of $9.90 to $10. The company expects adjusted EPS to range from $10.07 to $10.13, compared with prior guidance of $10 to $10.10. <\/p>\n

Litigation over talc-powder products continues to hang over the company, which has faced thousands of lawsuits from consumers alleging they developed cancer after using the products. Johnson & Johnson said in July that its LTL Management LLC subsidiary would appeal a New Jersey bankruptcy court\u2019s dismissal of LTL\u2019s attempt to resolve talc claims through bankruptcy. The company ultimately expects to appeal to the U.S. Supreme Court, Erik Haas, vice president of litigation, said on the call Tuesday, while it continues to \u201cdefend the meritless talc claims\u201d in court. <\/p>\n

Johnson & Johnson\u2019s stock
\n JNJ,
\n -1.77%<\/bg-quote>
\n fell 1% Tuesday morning and is down 11.8% in the year to date, while the S&P 500
\n SPX
\n has gained 13.7%. <\/p>\n

Of the 18 analysts tracked by FactSet who cover J&J shares, 10 have a buy rating, seven have a hold rating and one has an underweight, or sell, rating.<\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Johnson & Johnson on Tuesday posted better-than-expected third-quarter earnings and raised its profit guidance while downplaying concerns about how popular obesity drugs could affect its med-tech business. The New Brunswick, N.J.-based company posted net income of $4.309 billion, or $1.69 a share, for the quarter, after earnings of $4.31 billion, or $1.62 a share, in […]<\/p>\n","protected":false},"author":1,"featured_media":30940,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[32],"tags":[],"class_list":{"0":"post-30939","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"yoast_head":"\nJohnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business | Prosfunds<\/title>\n<meta name=\"description\" content=\"Johnson & Johnson on Tuesday posted better-than-expected third-quarter earnings and raised its profit guidance while downplaying concerns about how\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prosfunds.com\/?p=30939\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business | Prosfunds\" \/>\n<meta property=\"og:description\" content=\"Johnson & Johnson on Tuesday posted better-than-expected third-quarter earnings and raised its profit guidance while downplaying concerns about how\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prosfunds.com\/?p=30939\" \/>\n<meta property=\"og:site_name\" content=\"Prosfunds\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-17T18:52:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-17T18:52:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/10\/1697568769_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/prosfunds.com\/?p=30939#article\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/?p=30939\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\"},\"headline\":\"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business\",\"datePublished\":\"2023-10-17T18:52:48+00:00\",\"dateModified\":\"2023-10-17T18:52:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/prosfunds.com\/?p=30939\"},\"wordCount\":611,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/prosfunds.com\/?p=30939#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/prosfunds.com\/?p=30939\",\"url\":\"https:\/\/prosfunds.com\/?p=30939\",\"name\":\"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business | Prosfunds\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/#website\"},\"datePublished\":\"2023-10-17T18:52:48+00:00\",\"dateModified\":\"2023-10-17T18:52:50+00:00\",\"description\":\"Johnson & Johnson on Tuesday posted better-than-expected third-quarter earnings and raised its profit guidance while downplaying concerns about how\",\"breadcrumb\":{\"@id\":\"https:\/\/prosfunds.com\/?p=30939#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/prosfunds.com\/?p=30939\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/prosfunds.com\/?p=30939#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/prosfunds.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/prosfunds.com\/#website\",\"url\":\"https:\/\/prosfunds.com\/\",\"name\":\"Funding Factories\",\"description\":\"Latest Finance News and Updates\",\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/prosfunds.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/prosfunds.com\/#organization\",\"name\":\"Funding Factories\",\"url\":\"https:\/\/prosfunds.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"width\":780,\"height\":140,\"caption\":\"Funding Factories\"},\"image\":{\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/prosfunds.com\"],\"url\":\"https:\/\/prosfunds.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business | Prosfunds","description":"Johnson & Johnson on Tuesday posted better-than-expected third-quarter earnings and raised its profit guidance while downplaying concerns about how","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prosfunds.com\/?p=30939","og_locale":"en_US","og_type":"article","og_title":"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business | Prosfunds","og_description":"Johnson & Johnson on Tuesday posted better-than-expected third-quarter earnings and raised its profit guidance while downplaying concerns about how","og_url":"https:\/\/prosfunds.com\/?p=30939","og_site_name":"Prosfunds","article_published_time":"2023-10-17T18:52:48+00:00","article_modified_time":"2023-10-17T18:52:50+00:00","og_image":[{"width":1280,"height":640,"url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/10\/1697568769_social.jpeg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/prosfunds.com\/?p=30939#article","isPartOf":{"@id":"https:\/\/prosfunds.com\/?p=30939"},"author":{"name":"News Room","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6"},"headline":"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business","datePublished":"2023-10-17T18:52:48+00:00","dateModified":"2023-10-17T18:52:50+00:00","mainEntityOfPage":{"@id":"https:\/\/prosfunds.com\/?p=30939"},"wordCount":611,"commentCount":0,"publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/prosfunds.com\/?p=30939#respond"]}]},{"@type":"WebPage","@id":"https:\/\/prosfunds.com\/?p=30939","url":"https:\/\/prosfunds.com\/?p=30939","name":"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business | Prosfunds","isPartOf":{"@id":"https:\/\/prosfunds.com\/#website"},"datePublished":"2023-10-17T18:52:48+00:00","dateModified":"2023-10-17T18:52:50+00:00","description":"Johnson & Johnson on Tuesday posted better-than-expected third-quarter earnings and raised its profit guidance while downplaying concerns about how","breadcrumb":{"@id":"https:\/\/prosfunds.com\/?p=30939#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prosfunds.com\/?p=30939"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prosfunds.com\/?p=30939#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prosfunds.com\/"},{"@type":"ListItem","position":2,"name":"Johnson & Johnson beats earnings estimates and downplays obesity drugs\u2019 impact on its med-tech business"}]},{"@type":"WebSite","@id":"https:\/\/prosfunds.com\/#website","url":"https:\/\/prosfunds.com\/","name":"Funding Factories","description":"Latest Finance News and Updates","publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prosfunds.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/prosfunds.com\/#organization","name":"Funding Factories","url":"https:\/\/prosfunds.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","width":780,"height":140,"caption":"Funding Factories"},"image":{"@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","caption":"News Room"},"sameAs":["https:\/\/prosfunds.com"],"url":"https:\/\/prosfunds.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/30939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30939"}],"version-history":[{"count":1,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/30939\/revisions"}],"predecessor-version":[{"id":30941,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/30939\/revisions\/30941"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/media\/30940"}],"wp:attachment":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}